Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication;Kombination af aliskiren og losartan hos patienter med type 2-diabetes og nefropati - Sekundærpublikation

Ugeskrift for Laeger

Volumn 171, Issue 11, 2009, Pages 881-884

  Parving, Hans Henrik ^a   Persson, Frederik ^b   Lewis, Julia B ^c   Lewis, Edmund J ^d   Hollenberg, Norman K ^e  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449650949     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Parving H-H, Mauer M, Ritz E. Diabetic Nephropathy. In: Brenner BM, ed. Brenner and Rector's The Kidney. 8th edition. Boston, USA: WB Saunders, 2008;1265-98.
2. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2-diabetes and nephropathy. N Engl J Med 2001;345:861-9.
3. de Zeeuw D, Remuzzi G, Parving H-H et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-20.
4. Parving H-H, Andersen AR, Smidt UM et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;i:1175-9.
5. Parving H-H, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2-diabetes. N Engl J Med 2001;345:870-8.
6. Gaede P, Lund-Andersen H, Parving H-H et al. Effect of a multifactorial intervention on mortality in type 2-diabetes. N Engl J Med 2008;358:580-91.
7. Parving H-H, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2-diabetes and nephropathy. N Engl J Med 2008;358:2433-46.
8. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8.
9. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000;321:1440-4.
10. Andersen S, Blouch K, Bialek J et al. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58:2129-37.